Investors File Class Action Against MoonLake Immunotherapeutics Over Securities Violations

MoonLake Immunotherapeutics Faces Class Action Lawsuit

In a significant development for investors, MoonLake Immunotherapeutics, a company traded on NASDAQ under the ticker MLTX, is facing a class action lawsuit due to alleged violations of securities laws. The DJS Law Group has brought this matter to the attention of affected shareholders, urging those who purchased shares during the class period from March 10, 2024, to September 29, 2025, to come forward.

Background of the Lawsuit

The lawsuit arises from claims that MoonLake made false and misleading statements regarding its product, sonelokimab (SLK). The complaint highlights that the company asserted its drug was superior to existing therapies without credible evidence to support such claims. Once the results of a critical Phase 3 trial were released, they were described by analysts as “disastrous,” leading to broader concerns about the integrity of MoonLake’s public statements throughout the class period.

According to the document, these misleading statements substantially impacted shareholders and could have led to significant financial losses. As a result, the DJS Law Group has extended an invitation to shareholders who believe they have suffered from these events to participate in the legal proceedings. This class action not only allows for collective reclamation of losses but also aims at holding the company accountable for its actions.

Important Dates and Steps for Shareholders

The deadline for shareholders to enroll in this class action is approaching quickly, with a last opportunity on December 15, 2025. The DJS Law Group is actively reminding affected parties to register their status as shareholders to ensure they receive updates and further guidance through a portfolio monitoring system that tracks case developments.

It is crucial for shareholders to understand that participating as a lead plaintiff is not a requirement to recover any financial losses. The law group emphasizes that every shareholder who qualifies can be involved in the suit, ensuring that no one is left unrepresented.

Why DJS Law Group?

DJS Law Group is well-regarded for its commitment to enhancing investor returns through strategic advice and rigorous legal advocacy. Boasting a specialization in securities class actions, corporate governance disputes, and both domestic and international M&A appraisals, their expertise is recognized among some of the largest hedge funds and asset managers globally. The firm underscores the value of litigation claims as critical assets, necessitating respect and focused representation to secure beneficial outcomes for their clients.

For shareholders at risk of loss due to the actions of MoonLake, joining this class action represents an opportunity not only to reclaim funds but also to participate actively in seeking justice against corporate mismanagement. The firm has extended an open invitation to investors to reach out and discuss potential avenues of recovery.

Conclusion

As the landscape of investment litigation continues to evolve, instances like the one involving MoonLake Immunotherapeutics illustrate the importance of vigilance among investors and the crucial role of legal action in holding companies accountable for their commitments and statements. Affected shareholders are encouraged to act swiftly to secure their rights and restore their investments. To learn more about participating in this class action and monitoring updates, affected investors can contact DJS Law Group directly.

For inquiries, shareholders can reach out to:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

It's vital for investors to stay informed and engaged, ensuring they take all necessary steps to protect their interests in today's increasingly complex investment environment.